Abstract
Purpose: To compare outcomes in patients with treatment‐naïve neovascular age‐related macular degeneration (nAMD) receiving ranibizumab treat and extend (TE) with those receiving ranibizumab pro re nata (PRN) in a clinical setting.Methods: During this 12‐month retrospective, consecutive, comparative case series, patients received ranibizumab 0.5 mg according to a TE or PRN regimen. Monthly optical coherence tomography (OCT) evaluation was performed during the PRN regimen; retreatment criteria included recurrence of intra‐/subretinal fluid, or haemorrhages. During the TE regimen, initial treatment with 4‐week intervals was sequentially lengthened by 2 weeks until signs of choroidal neovascularization (CNV) activity recurred. Study end‐points included mean change in best corrected visual acuity (BCVA) and central retinal thickness (CRT), mean injection frequency and number of follow‐up visits attended.Results: Baseline characteristics were similar between the TE (n = 70) and PRN (n = 70) groups. Mean change in BCVA from baseline to Month 12 was significantly greater in the TE group than the PRN group (+0.18 ± 0.17 versus +0.07 ± 0.20, p < 0.001). Mean change in CRT from baseline to Month 12 was greater in the TE group than the PRN group (−116 ± 132 versus −58 ± 157 μm, p = 0.019). The number of follow‐up visits attended was significantly higher in the PRN group than the TE group (11.9 ± 1.1 versus 8.6 ± 1.9, p < 0.001), while patients in the TE group received more injections during the study than those in the PRN group (8.6 ± 1.9 versus 6.0 ± 1.9, p < 0.001).Conclusion: Ranibizumab administered using a TE regimen in treatment‐naïve patients with nAMD provided better visual outcomes with fewer clinic visits, compared with a PRN regimen.
Funding Information
  • Novartis Pharma

This publication has 31 references indexed in Scilit: